Low IGF-I bioavailability impairs growth and glucose metabolism in a mouse model of human PAPP-A2 deficiency and treatment with recombinant human IGF-I in PAPP-A2 deficient patients improves growth and bone mass and ameliorates glucose metabolism (72,73)
It helps: Reduce inflammation and support immune cell activity
They can assess your specific needs and recommend the best peptides and treatment plan for your situation
For example, in the active reducing environment of the cytoplasm, it is difficult to form intramolecular and intermolecular protein disulfides when the GSH:GSSG ratio exceeds 100:1
To learn more about usage limitations, visit our research-only disclaimer and associated information on wholesale research peptide purchasing
This product is strictly for research purposes only and is not approved for human consumption, medical use, or veterinary applications